Emerging therapeutic targets for NASH: key innovations at the preclinical level

References

• NCD-RisC. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642.
   PubMed Web of Science ®Google Scholar
• O’Neill S, O’Driscoll L Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 2015;16:1–12.
   PubMed Web of Science ®Google Scholar
• Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3490–3497.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
   PubMed Web of Science ®Google Scholar
• EASL, EASD, EASO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97 e10.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378.e5.
   Google Scholar
• Konerman MA, Jones JC, Harrison SA Pharmacotherapy for NASH: current and emerging. J Hepatol. . 2018;68:362–375.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol 2020;72:25–33.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39:2082–2093.
   PubMed Web of Science ®Google Scholar
• Arab JP, Arrese M, Trauner M Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol Mech Dis 2018;13:321–350.
   PubMed Web of Science ®Google Scholar
• Khan RS, Bril F, Cusi K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019.70:711–724.
   Google Scholar
• Marra F, Svegliati-Baroni G Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280–295.
   PubMed Web of Science ®Google Scholar
• Caballero F, Fernandez A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50:789–796.
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.
   PubMed Web of Science ®Google Scholar
• Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68:1063–1075.
   PubMed Web of Science ®Google Scholar
• Sanders FWB, Griffin JL De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev 2016;91:452–468.
   PubMed Web of Science ®Google Scholar
• Esquejo RM, Salatto CT, Delmore J, et al. Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models. EBioMedicine. 2018;31:122–132.
   PubMed Web of Science ®Google Scholar
• Stiede K, Miao W, Blanchette HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study. Hepatology. 2017;66:324–334.
   PubMed Web of Science ®Google Scholar
• Gao YS, Qian MY, Wei QQ, et al. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacol Sin. 2019.0:1-12.
   Web of Science ®Google Scholar
• Harriman G, Greenwood J, Bhat S, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci 2016;113:E1796.
   PubMed Web of Science ®Google Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463–1473.e6.
   PubMed Web of Science ®Google Scholar
• JS V L, Ghoshal S, DePeralta DK, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174–182 e5.
   PubMed Web of Science ®Google Scholar
• Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 2017;26:394–406 e6.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, paral. J Am Coll Cardiol. 2013;62:1154–1162.
   PubMed Web of Science ®Google Scholar
• Day EA, Ford RJ, Steinberg GR. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 2017;28:545–560.
   Google Scholar
• Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.
   PubMed Web of Science ®Google Scholar
• Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010;7:251–264.
   PubMed Web of Science ®Google Scholar
• Petersen MC, Vatner DF, Shulman GI Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572–587.
   PubMed Web of Science ®Google Scholar
• Miller CO, Yang X, Lu K, et al. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects. Am J Physiol Endocrinol Metab. 2018;315:E386–E393.
   PubMed Web of Science ®Google Scholar
• Softic S, Meyer JG, Wang G-X, et al. Dietary sugars alter hepatic fatty acid oxidation via transcriptional and post-translational modifications of mitochondrial proteins. Cell Metab. 2019;30:735–753.e4.
   PubMedGoogle Scholar
• Softic S, Gupta MK, Wang G-X, et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest 2017;127:4059–4074.
   PubMed Web of Science ®Google Scholar
• Tran C. Inborn errors of fructose metabolism. What can we learn from them? Nutrients. 2017;9:356
   Google Scholar
• Calle R, Bergman A, Somayaji V, et al. PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease. J Hepatol 2019;70:e69–e70.
   Web of Science ®Google Scholar
• Lebeaupin C, Vallee D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69:927–947.
   PubMed Web of Science ®Google Scholar
• Kim JY, Garcia-Carbonell R, Yamachika S, et al. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell. 2018;175:133–145 e15.
   PubMed Web of Science ®Google Scholar
• Lebeaupin C, Vallee D, Rousseau D, et al. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. Hepatology. 2018;68:515–532.
   PubMed Web of Science ®Google Scholar
• Shan B, Wang X, Wu Y, et al. The metabolic ER stress sensor IRE1alpha suppresses alternative activation of macrophages and impairs energy expenditure in obesity. Nat Immunol. 2017;18:519–529.
   PubMed Web of Science ®Google Scholar
• Tufanli O, Telkoparan Akillilar P, Acosta-Alvear D, et al. Targeting IRE1 with small molecules counteracts progression of atherosclerosis. Proc Natl Acad Sci U S A. 2017;114:E1395–E1404.
   PubMed Web of Science ®Google Scholar
• Zhang K, Wang S, Malhotra J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. Embo J. 2011;30:1357–1375.
   PubMed Web of Science ®Google Scholar
• Upton J-P, Wang L, Han D, et al. IRE1α cleaves select microRNAs during ER stress to derepress translation of proapoptotic caspase-2. Science. 2012;338:818–822.
   PubMed Web of Science ®Google Scholar
• Sandow JJ, Dorstyn L, O’Reilly LA, et al. ER stress does not cause upregulation and activation of caspase-2 to initiate apoptosis. Cell Death Differ. 2014;21:475–480.
   PubMed Web of Science ®Google Scholar
• Krumschnabel G, Sohm B, Bock F, et al. The enigma of caspase-2: the laymen’s view. Cell Death Differ. 2009;16:195–207.
   PubMed Web of Science ®Google Scholar
• Szabo G, Petrasek J Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 2019;19:477–489.
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–185.
   PubMed Web of Science ®Google Scholar
• Wree A, Eguchi A, McGeough MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910.
   PubMed Web of Science ®Google Scholar
• Csak T, Ganz M, Pespisa J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133–144.
   PubMed Web of Science ®Google Scholar
• Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037–1046.
   PubMed Web of Science ®Google Scholar
• Wei Q, Guo P, Mu K, et al. Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest 2015;95:804–816.
   PubMed Web of Science ®Google Scholar
• Dabbagh K, Steven Dodson G, Yamamoto L, et al. PS-111 - Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH). J Hepatol 2018;68:S60.
   Web of Science ®Google Scholar
• Mullard A NLRP3 inhibitors stoke anti-inflammatory ambitions. Nat Rev Drug Discov. 2019;18:405–407.
   PubMed Web of Science ®Google Scholar
• Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 2018;17:588–606.
   PubMed Web of Science ®Google Scholar
• Qiu S, Liu J, Xing F ‘Hints’ in the killer protein gasdermin D: unveiling the secrets of gasdermins driving cell death. Cell Death Differ. 2017;24:588–596.
   PubMed Web of Science ®Google Scholar
• Zhaolin Z, Guohua L, Shiyuan W, et al. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019;52:e12563.
   PubMed Web of Science ®Google Scholar
• Man SM, Karki R, Kanneganti T-D Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev 2017;277:61–75.
   PubMed Web of Science ®Google Scholar
• Khanova E, Wu R, Wang W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology. 2018;67:1737–1753.
   PubMed Web of Science ®Google Scholar
• Xu B, Jiang M, Chu Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol 2018;68:773–782.
   PubMed Web of Science ®Google Scholar
• Haneklaus M, O’Neill LAJ NLRP3 at the interface of metabolism and inflammation. Immunol Rev. 2015. p. 53–62.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• van der Meijden PEJ, Heemskerk JWM Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16:166–179.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Cedervall J The pro-inflammatory role of platelets in cancer. Platelets. 2018;29:569–573.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Jenne CN, Veldhuis ZJ, et al. Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver Int. 2017;37:1731–1737.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Kondo T, Matsuo R, et al. Platelet dynamics in the early phase of postischemic liver in vivo. J Surg Res 2008;149:192–198.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Murata S, Ohkohchi N Novel therapy for liver regeneration by increasing the number of platelets. Surg. Today. 2013;43:1081–1087.
   PubMed Web of Science ®Google Scholar
• Lalor PF, Herbert J, Bicknell R, et al. Hepatic sinusoidal endothelium avidly binds platelets in an integrin-dependent manner, leading to platelet and endothelial activation and leukocyte recruitment. Am J Physiol Gastrointest Liver Physiol. cited 2012 Dec 22. 2013;304:G469–78.
   PubMed Web of Science ®Google Scholar
• Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019;25:641–655.
   PubMed Web of Science ®Google Scholar
• Aryal B, Yamakuchi M, Shimizu T, et al. Therapeutic implication of platelets in liver regeneration -hopes and hues. Expert Rev Gastroenterol Hepatol. 2018;12:1219–1228.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Adams DH, Watson SP, et al. Platelets: no longer bystanders in liver disease. Hepatology. 2016;64:1774–1784.
   PubMed Web of Science ®Google Scholar
• Lesurtel M, Graf R, Aleil B, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–107.
   PubMed Web of Science ®Google Scholar
• Ozhan H, Aydin M, Yazici M, et al. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets. . 2010;21:29–32.
   PubMed Web of Science ®Google Scholar
• Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583–1591.
   PubMed Web of Science ®Google Scholar
• Scull CM, Hays WD, Fischer TH Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm 2010;7:53.
   Google Scholar
• Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549–564.
   PubMed Web of Science ®Google Scholar
• Baron SH Salicylates as Hypoglycemic Agents. Diabetes Care. 1982;5:64.
   PubMed Web of Science ®Google Scholar
• Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001;293:1673–1677.
   PubMed Web of Science ®Google Scholar
• Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321–1326.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco JB, Bartelink MLEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018. p. 763–816.
   Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019;41:407–477.
   Google Scholar
• Rosen V, Wozney JM, Wang EA, et al. Purification and molecular cloning of a novel group of BMPs and localization of BMP mRNA in developing bone. Connect Tissue Res. 1989;20:313–319.
   PubMed Web of Science ®Google Scholar
• Bier E, De Robertis EM EMBRYO DEVELOPMENT. BMP gradients: A paradigm for morphogen-mediated developmental patterning. Science. 2015;348:aaa5838.
   PubMed Web of Science ®Google Scholar
• Herrera B, Addante A, Sanchez A BMP signalling at the crossroad of liver fibrosis and regeneration. Int J Mol Sci. 2017;19(1):39.
   Web of Science ®Google Scholar
• Muñoz-Félix JM, González-Núñez M, Martínez-Salgado C, et al. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25years of trials and tribulations? Pharmacol Ther. 2015;156:44–58.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Bloch DB, Ten Dijke P, et al. Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol 2015;13:106.
   PubMed Web of Science ®Google Scholar
• Do N, Zhao R, Ray K, et al. BMP4 is a novel paracrine inhibitor of liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1220–7.
   PubMed Web of Science ®Google Scholar
• Breitkopf-Heinlein K, Meyer C, Konig C, et al. BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut. 2017;66:939–954.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Yang C, LeBleu VS, et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. Faseb J. 2007;21:256–264.
   PubMed Web of Science ®Google Scholar
• Choi TY, Khaliq M, Tsurusaki S, et al. Bone morphogenetic protein signaling governs biliary-driven liver regeneration in zebrafish through tbx2b and id2a. Hepatology. 2017;66:1616–1630.
   PubMed Web of Science ®Google Scholar
• Olsavszky V, Ulbrich F, Singh S, et al. GATA4 and LMO3 balance angiocrine signaling and autocrine inflammatory activation by BMP2 in liver sinusoidal endothelial cells. Gene. 2017;627:491–499.
   PubMed Web of Science ®Google Scholar
• Rowe IA, Galsinh SK, Wilson GK, et al. Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology. 2014;59:375–384.
   PubMed Web of Science ®Google Scholar
• Ribera J, Pauta M, Melgar-Lesmes P, et al. A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury. Am J Physiol Gastrointest Liver Physiol. 2017;313:G492–G504.
   PubMed Web of Science ®Google Scholar
• Desroches-Castan A, Tillet E, Ricard N, et al. Bone morphogenetic protein 9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting against hepatic fibrosis. Hepatology. 2019;70:1392–1408.
   PubMed Web of Science ®Google Scholar
• Wang CY, Xiao X, Bayer A, et al. Ablation of hepatocyte Smad1, Smad5, and Smad8 causes severe tissue iron loading and liver fibrosis in mice. Hepatology. 2019;70:1986–2002.
   PubMed Web of Science ®Google Scholar
• Tacke F Targeting hepatic macrophages to treat liver diseases. J Hepatol 2017;66:1300–1312.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Iimuro Y, Otogawa K, et al. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut. 2007;56:706–714.
   PubMed Web of Science ®Google Scholar
• Yang T, Chen SL, Lu XJ, et al. Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of gremlin and transforming growth factor beta1. Mol Med Rep. 2012;6:246–252.
   PubMed Web of Science ®Google Scholar
• Fan J, Shen H, Sun Y, et al. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol. 2006;207:499–505.
   PubMed Web of Science ®Google Scholar
• Arndt S, Wacker E, Dorn C, et al. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut. 2015;64:973–981.
   PubMed Web of Science ®Google Scholar
• Blazquez-Medela AM, Jumabay M, Bostrom KI Beyond the bone: bone morphogenetic protein signaling in adipose tissue. Obes Rev. 2019;20:648–658.
   PubMed Web of Science ®Google Scholar
• Saini S, Duraisamy AJ, Bayen S, et al. Role of BMP7 in appetite regulation, adipogenesis, and energy expenditure. Endocrine. 2015;48:405–409.
   PubMed Web of Science ®Google Scholar
• Oral Abstracts (Abstracts 1–288). Hepatology. 2019;70:1–187.
   PubMedGoogle Scholar
• Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism. 2014. p. 895–902.
   Google Scholar
• FDA. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry DRAFT GUIDANCE. FDA Off. Doc. 2018
   Google Scholar
• Abeles RD, Mullish BH, Forlano R, et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther. 2019; 49:1077–1085.
   Web of Science ®Google Scholar
• Palma E, Doornebal EJ, Chokshi S Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int. 2019. 13:51–57.
   Google Scholar
• Feaver RE, Cole BK, Lawson MJ, et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight. 2016;1:e90954.
   PubMed Web of Science ®Google Scholar
• Ouchi R, Togo S, Kimura M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab. 2019;30:374–384.e6.
   PubMedGoogle Scholar
• Skubic C, Ž D, Rozman D Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol. 2018.14:831–841.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Coste A, Poordad F, et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2018;16:1983–1991.e3.
   PubMedGoogle Scholar